AttoQuest

See Resistance Sooner. Treat Smarter.

AttoQuest is revolutionizing diagnostics with ultra-fast, single-molecule spectroscopy. Built for hospital labs, our platform delivers rapid detection of antibiotic resistance, giving clinicians the insights they need to make timely, evidence-based decisions for serious infections like sepsis and pneumonia. By seeing resistance earlier, AttoQuest helps reduce diagnostic delays, improve treatment outcomes, and support smarter use of antibiotics. AttoQuest integrates seamlessly into existing lab workflows, making it easy to adopt in real-world clinical settings. Our technology supports global efforts to combat antimicrobial resistance. Scalable, intuitive, and designed for real-world impact, AttoQuest is redefining how we detect, respond to, and contain infectious threats.

Achievements:

- AEA Ignite grant awarded, licensing discussions, IHealthE Excite grant from the Innovation Catalyst program

Team: Emma Sierecki, Founder and CSO; Yann Gambin, Founder and CTO; Dimitri Aubert, CEO

Dimitri Aubert, CEO; Emma Sierecki, Founder and CSO.